10-Q · May 8, 2026
Cumberland Pharmaceuticals reported a significant decline in Q1 2026 net revenues of $9.1 million, down from $11.7 million in Q1 2025, largely affected by the absence of a $3 million milestone payment included in the…
Earnings analysis · 10-Q
CPIX earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The filing reflects a fundamental transition following the July 1, 2026 divestiture of commercial products for $100 million: the company no longer has approved products or product revenue and is now dependent on…
Read full summary
The filing reflects a fundamental transition following the July 1, 2026 divestiture of commercial products for $100 million: the company no longer has approved products or product revenue and is now dependent on clinical development. Reported EPS was a loss of $0.20 and continuing-operations revenue was $166,458, but comparisons with the prior $11 million Q2 2025 revenue and $(0.05) EPS are distorted by the Apotex-related reclassification. Management believes the $100 million proceeds and anticipated interest income will fund operations for the foreseeable future, while warning that clinical delays or additional trials could require further financing.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.2
What stood out
-
$100M divestiture funds clinical pipeline
The company completed the divestiture of its FDA-approved commercial products on July 1, 2026 for aggregate cash consideration of $100 million, providing funding for clinical development and general corporate purposes.
-
Liquidity outlook extends foreseeable future
Management stated that the $100 million Transaction proceeds, together with anticipated interest income, are expected to be sufficient to fund operations for the foreseeable future based on current development plans.
-
42.38% insider ownership
The company’s officers and directors controlled approximately 42.38% of common stock as of June 30, 2026, providing substantial insider ownership alignment, although it also concentrates voting influence.
-
New $5M share repurchase authorization
On July 13, 2026, the board authorized a new open-market repurchase program of up to $5 million, replacing the prior $10 million program; no shares were purchased during April, May, or June 2026.
What to watch
-
Commercial revenue base eliminated
The July 1, 2026 divestiture eliminated the company’s FDA-approved commercial products and product revenue, transforming it into a clinical-stage company dependent on candidates that have not been approved for sale. The transaction proceeds were $100 million, but management expects significant operating losses for the foreseeable future.
-
Clinical development may require more capital
Management stated that the $100 million Transaction proceeds may not be sufficient if clinical programs experience unforeseen complications, delays, or require additional trials. Additional financing may be needed, potentially through equity or debt, strategic alliances, or licensing arrangements.
-
Execution and regulatory dependence
The company’s future success is now entirely dependent on clinical development, regulatory approval, and commercialization of unapproved product candidates. The company had 88 employees as of June 30, 2026 and relies substantially on third parties including investigators, universities, medical institutions, CROs, and strategic partners.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that the $100 million Transaction proceeds, together with anticipated interest income, are expected to fund operations for the foreseeable future based on current development plans.
Earlier filings 4
10-K · March 9, 2026
Cumberland grew net revenues to $44.52M in 2025 (up $6.65M or 17.6% vs. 2024) driven by Sancuso, Vibativ and the late-2025 addition of Talicia, while maintaining a high gross margin of 85.0%. Operating loss narrowed to…
10-Q · November 7, 2025
Cumberland reported Q3 net revenues of $8,292,362 (down from $9,085,826 a year ago) and a Q3 net loss attributable to common shareholders of $1,940,764 (basic/diluted loss per share $0.13). Gross margin remained very…
10-Q · August 8, 2025
Cumberland reported Q2 net revenues of $10,837,363, up $988,514 (≈10.0%) vs. Q2 2024 ($9,848,849) but down $875,692 (≈7.5%) vs. Q1 2025 ($11,713,055). Gross margin remained high at ~81.4% (COGS $2,011,389) while the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.